Therapeutic Area: Nephrology

Primary Hyperoxaluria Type 1 (PH1) – Alnylam Act®

Alnylam Act® is a sponsored, no-charge genetic testing and counseling program for patients with a family history or suspected diagnosis of PH1. The Alnylam Act® program was created to provide access to genetic testing and counseling to patients as a way to help people make more informed decisions about their health.

– While Alnylam provides financial support for this program, tests and services are performed by independent third parties.
– Healthcare professionals must confirm that patients meet certain criteria to use the program.
– Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient-identifiable information. Alnylam may use healthcare professional contact information for research purposes.
– Both genetic testing and genetic counseling are available in the US and Canada.
– Healthcare professionals or patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Alnylam product.
– No patients, healthcare professionals, or payers, including government payers, are billed for this program.

Disease/Condition(s): Primary Hyperoxaluria Type 1 (PH1)

Therapeutic Area: Nephrology

Program Sponsor

Participating Lab